secwatch.observer — SEC 8-K summary
======================================

Issuer:     ProPhase Labs, Inc. (PRPH)
CIK:        0000868278
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023344
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ProPhase Labs Q2 net loss narrows to $4.5M, gross margin turns positive; patent for BE-Smart; crypto treasury approved
--------------------------------------------------------------------------------

- Q2 revenue $1.2M vs $1.5M YoY; net loss from continuing ops $4.5M ($0.11/share) vs $5.5M ($0.29/share).
- Gross margin improved to 58.9% from (10.3)% YoY; operating expenses cut 35% YTD; sale of PMI generated $8.7M gain.
- U.S. patent granted for BE-Smart esophageal adenocarcinoma test in August 2025; accelerates commercialization.
- Board approved crypto treasury strategy including Bitcoin; proposed authorized share increase to 1 billion for flexibility.
- Stockholders' equity rose to $11.5M (from $7.4M at year-end); cash $169K; Crown Medical estimates $50M recovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/868278/000164117225023344/0001641172-25-023344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/868278/000164117225023344/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer